Long-term clinical outcome after intracoronary application of bone marrow-derived mononuclear cells for acute myocardial infarction: migratory capacity of administered cells determines event-free survival.
about
Stem cell treatment for acute myocardial infarctionBone Marrow-Derived Stem Cells: a Mixed Blessing in the Multifaceted World of Diabetic ComplicationsImpact of Timing following Acute Myocardial Infarction on Efficacy and Safety of Bone Marrow Stem Cells Therapy: A Network Meta-AnalysisConcise Review: Review and Perspective of Cell Dosage and Routes of Administration From Preclinical and Clinical Studies of Stem Cell Therapy for Heart DiseaseExploiting the Pleiotropic Antioxidant Effects of Established Drugs in Cardiovascular DiseaseProgramming and reprogramming a human heart cellFifteen years of bone marrow mononuclear cell therapy in acute myocardial infarctionCell surface glycoengineering improves selectin-mediated adhesion of mesenchymal stem cells (MSCs) and cardiosphere-derived cells (CDCs): Pilot validation in porcine ischemia-reperfusion model.Relationships of growth factors, proinflammatory cytokines, and anti-inflammatory cytokines with long-term clinical results of autologous bone marrow mononuclear cell transplantation in STEMITime course of VCAM-1 expression in reperfused myocardial infarction in swine and its relation to retention of intracoronary administered bone marrow-derived mononuclear cells.The challenges of autologous cell therapy: systemic anti-thrombotic therapies interfering with serum coagulation may disable autologous serum-containing cell products for therapeutical use.An emerging consensus on cardiac regeneration.Advanced Therapy Medicinal Products: How to Bring Cell-Based Medicinal Products Successfully to the Market - Report from the CAT-DGTI-GSCN Workshop at the DGTI Annual Meeting 2014.Metabolism Regulates Cellular Functions of Bone Marrow-Derived Cells used for Cardiac Therapy.Rapid assay of stem cell functionality and potency using electric cell-substrate impedance sensingBiomaterial strategies to improve the efficacy of bone marrow cell therapy for myocardial infarction.Discrepancy between short-term and long-term effects of bone marrow-derived cell therapy in acute myocardial infarction: a systematic review and meta-analysis.Comparison of three different types of scaffolds preseeded with human bone marrow mononuclear cells on the bone healing in a femoral critical size defect model of the athymic rat.Position Paper of the European Society of Cardiology Working Group Cellular Biology of the Heart: cell-based therapies for myocardial repair and regeneration in ischemic heart disease and heart failure.Evolving targeted therapies for right ventricular failure.Novel cardioprotective and regenerative therapies in acute myocardial infarction: a review of recent and ongoing clinical trials.Targeting vascular (endothelial) dysfunction.Stem Cell Therapy for Myocardial Infarction 2001-2013 Revisited.Stem Cell Technology in Cardiac Regeneration: A Pluripotent Stem Cell PromiseHuman Umbilical Cord-Derived Mesenchymal Stromal Cells Improve Left Ventricular Function, Perfusion, and Remodeling in a Porcine Model of Chronic Myocardial Ischemia.Novel thiazolidinedione mitoNEET ligand-1 acutely improves cardiac stem cell survival under oxidative stress.Cardioprotective role of growth/differentiation factor 1 in post-infarction left ventricular remodelling and dysfunction.Bone marrow-derived cells and their conditioned medium induce microvascular repair in uremic rats by stimulation of endogenous repair mechanisms.Effect of stromal cell-derived factor-1 on myocardial apoptosis and cardiac function recovery in rats with acute myocardial infarctionBone marrow-derived cells for cardiovascular cell therapy: an optimized GMP method based on low-density gradient improves cell purity and function.The effect of injection using narrow-bore needles on mammalian cells: administration and formulation considerations for cell therapiesLong term outcome after mononuclear bone marrow or peripheral blood cells infusion after myocardial infarction.Frontiers in the management of coronary artery disease: bioabsorable scaffolds, regenerative medicine, and gene therapy.Active Stromal Cell-Derived Factor 1α and Endothelial Progenitor Cells are Equally Increased by Alogliptin in Good and Poor Diabetes Control.Pursuing meaningful end-points for stem cell therapy assessment in ischemic cardiac disease.Reversal of Bone Marrow Mobilopathy and Enhanced Vascular Repair by Angiotensin-(1-7) in Diabetes.Bone Marrow Mononuclear Cells Transfer for Patients after ST-Elevated Myocardial Infarction: A Meta-Analysis of Randomized Control Trials.COMPARE CPM-RMI Trial: Intramyocardial Transplantation of Autologous Bone Marrow-Derived CD133+ Cells and MNCs during CABG in Patients with Recent MI: A Phase II/III, Multicenter, Placebo-Controlled, Randomized, Double-Blind Clinical Trial.
P2860
Q24186920-78EE39BD-1677-4404-B035-4922C20D3D35Q26749552-8AD87D04-D46E-433D-9652-50ED91E099ACQ26771257-2FCECE1D-AFC0-481D-9C8E-18ED68B6E39FQ26774781-657D5381-6434-4151-81D8-AE92A9A33DA5Q26801173-62FFEACA-BF23-4862-88F1-9E74F4154D6FQ26823933-2DE3788B-EC92-4720-BC0C-00E9036C4A24Q29994502-5CA54669-1C67-4504-8029-E9083838CC90Q30683188-0746F7D0-599E-4E89-93CE-FC5E2922C970Q33739109-8ED6B941-4048-4239-9E9E-A6B82689BA05Q33811749-2CBCC766-3043-4B3D-B1F5-7568A122ED83Q35250837-DFEEE43D-4F0C-4373-B0CD-C1DD86B52A78Q35565809-2E467452-9D00-423B-B39E-DB554868E174Q35789528-13E34ACB-E5BA-4A3E-86DD-561A643D50EBQ36008423-756AC4ED-85DE-4129-B200-7C4A8F86721CQ36126357-0F11FE3C-5196-4D81-B415-8B92B378C80EQ36127860-560FE835-F437-443E-BD92-BDB1CE1C1B1DQ36169861-1604E357-06B2-42C5-8B31-887731E96F1DQ36382712-BA95D469-C402-47E7-91F3-502D47813276Q37016190-F7F15387-AE7E-4282-8DC3-0BC44B1720D1Q38559308-4B9760F7-A614-4954-A3EA-7B9B4822642FQ38801590-5DF4EA9B-449A-4835-BFD9-017D423CAA38Q38836199-7622AFDE-C941-4691-8BE7-92DD2B37CBB0Q38992231-59608784-0E89-4CEB-A1B4-0476408D8D13Q39124190-E2B4A031-8483-4954-9444-B81C5609DE1EQ39662200-FEBD755E-6E46-41E7-8367-88E2F6888254Q40084187-E0F3883A-CAFD-4E6D-AF88-899B98052A8FQ41333298-8B1D9D2E-2245-44C8-8E15-714CBD26802BQ41529629-2C2B66F4-9325-4F37-8638-03BDC0690B1CQ41811873-4E629CF5-7D47-4867-AFA4-49988A793D99Q41881618-ACBEB83B-631A-476B-9D87-3C04A52B01DFQ42396489-D14D34C6-E60F-4565-9FEE-02E4887DD764Q43994483-B7BC618B-D4FC-4422-842C-23BB5DC6AF97Q45871903-7BCFCE2A-6029-44CF-87CC-E15CD68154F7Q47131763-33A1E6C2-3867-4104-A616-70D2291159F7Q49288386-38C4154E-3B58-414D-9AFD-A16FE68ACFA1Q51321906-CF4B735A-5E11-4054-9E6C-7CA3F1B91046Q55348173-B2E354A7-E414-48F1-B783-8C64D9F77C07Q55383848-0B77D51E-9F66-4616-871A-4A6B56B75D19
P2860
Long-term clinical outcome after intracoronary application of bone marrow-derived mononuclear cells for acute myocardial infarction: migratory capacity of administered cells determines event-free survival.
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Long-term clinical outcome aft ...... etermines event-free survival.
@ast
Long-term clinical outcome aft ...... etermines event-free survival.
@en
type
label
Long-term clinical outcome aft ...... etermines event-free survival.
@ast
Long-term clinical outcome aft ...... etermines event-free survival.
@en
prefLabel
Long-term clinical outcome aft ...... etermines event-free survival.
@ast
Long-term clinical outcome aft ...... etermines event-free survival.
@en
P2093
P2860
P50
P356
P1476
Long-term clinical outcome aft ...... etermines event-free survival.
@en
P2093
Albrecht Elsässer
Charlotte Mayer-Wehrstein
Christian W Hamm
Christine Barth
Daniel Sedding
Detlef G Mathey
Iris Burck
Jiangtao Yu
REPAIR-AMI Study Group
Rainer Hambrecht
P2860
P304
P356
10.1093/EURHEARTJ/EHU062
P577
2014-02-25T00:00:00Z